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Background: Breast cancer expressing all three diagnostic markers (estrogen receptor, ERþ; progester-
one receptor, PgRþ; human epidermal growth factor receptor 2, HER2þ) is insufﬁciently characterized
even though it is a sizable patient population. An invasive ductal carcinoma (IDC) triple-positive breast
cancer (TPBC) case is genomically proﬁled and the literature reviewed to illustrate the molecular het-
erogeneity and interconnectivity of the disease biology.
Presentation of case: A premenopausal, 48-year-old female with no family history of breast cancer pre-
sented with IDC (1.5 cm primary tumor, 5 nodal metastases of 23 axillary nodes examined, pT1cN2a
AJCC/UICC stage). Immunohistochemical analysis showed strong staining of all three diagnostic markers
(ER 4þ , PgR 4þ , HER2 3þ). HER2 ampliﬁcation was conﬁrmed by FISH (HER2/cen17 ratio¼5.7). Ki-67
nuclear staining was detected in 30% of tumor cells.
Genomic ﬁndings: ERRB2 was ampliﬁed (9 copies) and activated by mutation (S310F). The PI3K pathway
was activated through a catalytic subunit activating mutation (PIK3CA-E545K), a regulatory subunit
ampliﬁcation (PIK3R2, 8 copies) and an AKT1 activating mutation (E17K). Additional alterations were
identiﬁed (IGF1R, SMO, DOT1L, ERG, CEBPA). BRCA1/2 germline abnormalities were not identiﬁed. Sur-
gery followed by adjuvant therapy APHINITY trial (Taxotere, carboplatin, Herceptin, 50% chance of per-
tuzumab) and anti-estrogen therapy. These therapies either directly (ER, HER2) or indirectly (PI3K) target
the patient-speciﬁc tumor biology. The patient is free of disease 40 months post-surgery.
Conclusion: Genomic proﬁling detected multiple alterations impinging on the PI3K signaling pathway
and gene regulation suggesting important contributions of these processes to this TPBC, despite two
dominant pathway engagements (ER, HER2).
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer is a spectrum of diseases stratiﬁed by three im-
munohistochemistry (IHC) tumor markers: estrogen receptor (ER),
progesterone receptor (PgR), and the human epidermal growth
factor receptor-2 (HER2/neu, erbB2) [1,2]. This coarse deﬁnition of
tumor drivers has enabled dramatic improvements in overall
survival by matching patients with therapies that target their
disease biology. Half of the HER2þ breast cancer population is
reported to have at least one hormone receptor (ER, PgR) involved
(HRþ/HER2þ; 4–5% of breast cancer) [3–5]. Breast cancer ex-
pressing all three markers, triple-positive breast cancer (TPBC;
ERþ/PgRþ/HER2þ), has received less attention than otherLtd. This is an open access article u
urray).segments despite being a signiﬁcant fraction of breast cancer. For
TPBC, the contributions of ER and HER2 to the disease are well-
established while the role of PgR is less clear. The expression of
PgR correlates with younger ERþ/HER2þ patients [6] and trends
with better DFS [7]. Analysis of early breast cancer patients
(n¼1074) showed a strong association of PgR expression with
negative HER2 status [8]. Further, the study found ERþ tumors
without PgR were more likely to be HER2þ . Although these are
only correlations, the associations indicate distinct underlying
biologies.
FDA-approved therapies are available to TPBC patients. The
monoclonal antibody trastuzumab targets homodimeric HER2
signaling and is approved for adjuvant treatment of HER2þ/HRþ
breast cancer in combination with chemotherapy based on the
HERA clinical trial and is effective for TPBC patients (984 TPBC
patients, one year of trastuzumab, hazard ratio¼0.63) [7]. Tras-
tuzumab is also approved for metastatic HER2þ/HRþ breastnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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crease in progression-free survival (PFS) (5.6 vs 3.8 months) when
trastuzumab was added to anastrozole [9]. Lapatinib is also ap-
proved for metastatic HER2þ/HRþ breast cancer in combination
with letrozole for postmenopausal patients based on a PFS ad-
vantage over letrozole alone (n¼219, 8.2 vs 3.0 months) [10]. In
neoadjuvant treatment of operable HER2þ/HRþ tumors, adding
anti-HER2 therapies to chemotherapy showed signiﬁcant patho-
logical complete response rate (28–44%) and longer overall survi-
val for responsive patients (e.g. GeparQuinto [11] and NeoALTTO
[12] trials). Some studies suggest a superiority of trastuzumab over
lapatinib as the anti-HER2 component in neoadjuvant therapy
[11]. On-going clinical studies are building the case for eliminating
the cytotoxic chemotherapy component of neoadjuvant regimens
and rely solely on targeted therapies [13,14]. Trastuzumab has
been conjugated to a microtubule inhibitor to make the antibody-
drug conjugate ado-trastuzumab emtansine (T-DM1). This drug is
approved for metastatic HER2þ breast cancer patients based on
the EMILIA study (n¼991) [15] which found that HER2þ patients
with HR involvement had better overall survival than those
without (hazard ratio 0.62 vs 0.75, FDA label). The monoclonal
antibody pertuzumab binds HER2 at a site distinct from trastu-
zumab and blocks heterodimer signaling (e.g. HER2/HER3) [16].
The trastuzumab/pertuzumab/docetaxel drug combination is ap-
proved for early HER2þ breast cancer in neoadjuvant settings
(NEOSPHERE trial, n¼417) [17] and in ﬁrst-line treatment of me-
tastatic HER2þ breast cancer patients based on the CLEOPATRA
trial (n¼808, 15.7 months median overall survival increase) with
HER2þ/HRþ patients receiving clinical beneﬁt but less than
HER2þ/HR- patients [18,19]. This drug combination is being as-
sessed in the adjuvant setting (APHINITY trial) [16] in which the
reported patient is enrolled. Patients are subsequently treated
with anti-hormonal therapies to suppress ER-dependent disease
processes. Although these adjuvant treatment options are avail-
able to patients with TPBC, relapse is not uncommon which
challenges how well-matched they are to TPBC disease biology.Table 1
Genomic proﬁling of the TPBC tumor toward genes known to be somatically altered
in human solid tumors that are validated targets for therapy and/or that are drivers
of oncogenesis (236 genes and 47 introns of 19 genes involved in rearrangements).
The analysis provided mutant allele frequencies in the context of an estimated
specimen tumor content (50% in this case).
Gene Mutation Allele
frequency
Notes2. Methods
2.1. Genomic proﬁling
BRCA germline abnormalities were assessed by Comprehensive
BRACAnalysiss (Myriad Genetic Laboratories) [20]. Genomic pro-
ﬁling using FoundationOne [21] (Foundation Medicine, Cambridge,
MA) sequenced the coding region of 236 genes as well as 47 in-
trons of 19 genes involved in rearrangements to a typical median
depth of coverage of greater than 500 (Supplemental Methods,
Supplemental Table S1).ERBB2 ampliﬁcation copy
number¼9
HER2 receptor tyrosine kinase
ERBB2 S310F 11.0% HER2 receptor tyrosine kinase
PIK3CA E545K 2.0% PI3K catalytic subunit
PIK3R2n ampliﬁcation copy
number¼8
PI3K regulatory subunit
AKT1 E17K 13.0% PI3K effector kinase
IGF1Rn P190S 51.0% Receptor tyrosine kinase
SMOn G16_L17insL 27.0% Smoothen G protein-coupled
receptor
DOT1Ln Y194C 7.0% H3K79 methyltransferase
Disrupter of telomere silencing-1
ERGn G458E 51.0% Transcription factor, ETS-related
gene
CEBPAn P196_P197insHP 30.0% Transcription factor
CCAAT/enhancer binding protein
α
n Variants of unknown signiﬁcance – alterations not yet sufﬁciently linked to
disease progression to inform treatment decisions.3. Results
3.1. Clinical presentation
A 48-year-old premenopausal female with no family history of
breast cancer identiﬁed a lump on her left breast by self-examination.
Three masses were detected in the left breast by mammography with
the index tumor scored as BI-RADS category 3. Microscopic analysis of
an ultrasound guided core biopsy of the index tumor detect invasive
ductal carcinoma. Immunohistochemical testing of the index tumor
showed the following: strong ER staining (3þ) in 100% of cells, strong
PgR staining (2þ) in 90% of the cells, and moderate HER-2 over-
expression (2þ staining). Fluorescence in situ hybridization (FISH)
analysis determined ERRB2 (HER2) was ampliﬁed based on the HER-
2/cen17 ratio (16.2/3.2¼5.7) (Accupath Diagnostic Laboratories usingVysis PathVysion HER2 DNA Probe Kit). Of HER2þ disease, a ratio
greater than 5 is considered high [22]. Ki67 immunoperoxidase study
of 300 tumor cell nuclei showed nuclear staining in 91 nuclei (30.3%).
The patient underwent a bilateral mastectomy (contralateral breast
for prophylactic purposes). The tumor was 1.5 cm by microscopic
examination. Resected margins were negative for invasive tumor
(pancytokeratin analysis). Hormone receptor status were both highly
positive (4þ , 490%). HER2 status was also positive (3þ ASCO/CAP).
Axillary node dissections (Levels 1 and 2) were completed during the
same surgery. Five of 23 axillary nodes were involved with the largest
diameter of metastasis was 0.5 cm. Intraoperative palpation of Level
3 axillary nodes identiﬁed no additional abnormal nodes. These
ﬁndings deﬁne the disease as TPBC AJCC/UICC stage pT1cN2a.
3.2. Genomic analyses
BRCA1 and BRCA2 germline mutations were ruled out using the
Myriad Genetics Comprehensive BRACAnalysis assessment [20].
Comprehensive genomic proﬁling (CGP) was performed with a
hybrid-capture based method and subsequent sequencing to high,
uniform coverage [21] (FoundationOne, Foundation Medicine,
Cambridge, MA) (Table 1). This approach tested for dysregulation
of genes known to be somatically altered in human solid tumors
that are validated targets for therapy or are known drivers of on-
cogenesis (236 genes and 47 introns of 19 genes involved in re-
arrangements) (Supplemental Table S1). In this setting, CGP may
identify altered tumor suppressor genes, which may be either
somatic or germline altered, and focused testing to deﬁnitively
identify germline events is recommended in such a case [23].
3.3. Adjuvant therapy
This patient enrolled in the APHINITY clinical trial assessing the
efﬁcacy of pertuzumab in the adjuvant setting. The patient received
TCH therapy (Taxotere©/carboplatin/Herceptin©) with a 50% chance
of receiving pertuzumab (double blind/placebo controlled). The pa-
tient had facial rashes are the ﬁrst (loading) dose of study drug. She
underwent 5 weeks of external beam radiation therapy, followed by
tamoxifen, consistent with her premenopausal status but switched to
an aromatase inhibitor (Aromasin©) with ovarian ablation after 1 year
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[24]. With 42 months of follow-up, the patient has had no signs of
recurrence and remains in the clinical trial.4. Discussion
Triple-positive breast cancer is emerging as a distinct tumor
biology [3–5,25,26]. Gene expression analysis stratiﬁes HER2þ
disease into subpopulations which indicates that there are distinct
biological proﬁles [25]. Further analysis reveals that TPBC is en-
riched for luminal gene clusters (e.g. GATA3, BCL2, ESR1) [27]. An
analysis of overall survival for more than 123,000 breast cancer
patients revealed similar outcomes between ERþ/PgRþ/HER2-
negative and TPBC patient populations with a small survival ad-
vantage for patients without HER2 involvement (1–2.2%) [28]. This
ﬁnding is somewhat surprising considering the adverse effect of
HER2 expression in breast cancer overall. However, there is a
spectrum of HER2 dysregulation in HER2þ disease with lower
ampliﬁcation typically found in tumors having estrogen receptor
involvement [22]. The HERA trastuzumab adjuvant clinical trial
showed that HER2þ patients with hormone receptor involvement
have signiﬁcantly better DFS from trastuzumab treatment than
HR- patients [29]. More recently, HER2þ/ERþ patients have been
stratiﬁed by HER2/cen17 FISH ratios. HER2þ patients with low
ratios (2–5) derived less beneﬁt from adjuvant trastuzumab
treatment than HER2þ/ER- patients while those with a high ratios
derived as much beneﬁt as HER2þ/ER- patients [22]. There is a
striking difference in relapse patterns of trastuzumab treated pa-
tients based on HR status. Patients with HER2þ/HR- tumors had a
substantial decrease in early relapses but not for later recurrences
while TPBC patients have a more modest initial response but have
a sustained reduction in the risk of later relapse [7,29]. In the
neoadjuvant setting, TPBC patients were found to be less re-
sponsive to trastuzumab treatment relative to HER2þ/HR- pa-
tients (50% pathological complete response for HER2þ/HR- vs 31%
HER2þ/HRþ) [30]. In the metastatic setting, TPBC patients are
less responsive to hormonal treatment than HER2-/HRþ disease
[5,31,32]. From clinical and non-clinical perspectives, TPBC ap-
pears to have distinct tumor biology which may require therapies
speciﬁcally tailored to it.
Evaluation of the tumor biology of the patient in this case study
established that the tumor engages redundant mechanisms to
activate oncogenic signaling pathways. HER2 was activated by two
mechanisms – ampliﬁcation and mutation. By current standards,
the patient had a high level of HER2 ampliﬁcation (FISH45) [22].
Although copy number is not always well-correlated with FISH
ratios [22], the patient did have a high ERRB2 copy number. The
ERBB2 S310F mutation is a rare event in breast cancer (2 of 1339
breast cancer samples; COSMIC, September 2015) and ERRB2
mutations throughout the gene were found in 2.4% of 5,605 me-
tastatic breast cancers [33,34]. The S310F ERRB2 mutation is
thought to be an oncogenic driver [35]. The genomic proﬁling also
identiﬁed alterations impinging on the phosphatidyl inositol-3
kinase (PI3K) pathway. This ﬁnding is not surprising because the
PI3K pathway integrates signals from environmental cues (e.g.
growth factors) to affect speciﬁc intracellular responses and is one
of the most frequently mutated pathways in cancer [36, 37]. What
is striking is the number of PI3K pathway alterations that occur in
the TPBC patient's tumor (PIK3CA, PIK3R2, AKT1, IGF1R). The PI3K
catalytic domain mutation (PIK3CA-E545K) is at one of the two
common mutational sites known to be oncogenic [36] and occurs
in 5% of breast cancer (62 of 1339 samples; COSMIC, September
2015). This mutation is reported to reside almost exclusively in the
luminal A (ERþ) breast cancer [27]. The PI3K pathway is normally
attenuated by one of two regulatory subunit (PIK3R1, PIK3R2) withPIK3R2-containing PI3K complexes having substantially higher
basal activity than those with PIK3R1 [38]. Increased expression of
PIK3R2 occurs in breast and colon cancers which leads to in-
creased PI3K pathway activation [36,38]. Although PIK3R2 ampli-
ﬁcations are not frequently reported in breast cancer (COSMIC,
September 2015), they are common in other types of cancer (e.g.
23% of lymphoma, n¼60 [39]). The downstream signaling protein
AKT1, a known PI3K effector, is activated by an E17K mutation
which is not infrequent in breast cancer (2%; COSMIC, September
2015). IGF1R is reported to facilitate PI3K pathway signaling in
breast cancer [40] and IGFR is frequently upregulated in the
HER2þ/HRþ breast cancer [27]. Mutations of IGF1R are reported
to be rare [41] and the functional consequences of the observed
IGF1R P190S mutation are not well-described but it is modeled to
be at the end of a dimer interface [42]. In addition to affecting
tumor cell proliferation, enhanced PI3K signaling can contribute to
altering cellular phenotypes which expands tumor cell hetero-
geneity [43]. Taken together, multiple mutations and ampliﬁca-
tions in this patient's TPBC tumor impinge upon the HER2 and
PI3K pathways, presumably insuring robust and sustained path-
way engagement.
Additional altered genes in the TPBC tumor have been reported
to be associated with disease progression (SMO, DOT1L, ERG,
CEBPA) and can be grouped together as regulators of tumor cell
phenotypic properties. SMO has a role in breast cancer tumor-
igenesis and metastasis by regulating breast cancer stem-like cells
[44]. DOT1L is an epigenetic epithelial-mesenchymal transition
regulators critical to breast cancer disease progression [45]. The
ETS family transcription factor ERG is an oncogene [46,47]. The
observed ERG mutation occurs in the C-terminal transactivation
domain which is reported to function in the allosteric auto-
inhibition of the DNA-binding domain [47]. The leucine zipper
transcription factor CEBPA is known to cause leukemic transfor-
mation [48]. These four mutations may occur to engage a pheno-
type switching program [49] that facilitates disease progression.5. Conclusion
Large cancer genomic studies of speciﬁc cancer histologies
describe the daunting heterogeneity of the diseases at a popula-
tion level [50,51]. The current study shows that multiple me-
chanisms are engaged which are expected to alter three cellular
processes (HER2 and PI3K pathway signaling; transcriptional
regulation). The apparent order to the TPBC patient's tumor biol-
ogy provides hope that as we assemble molecular portraits of
patients’ diseases, speciﬁc therapies can be rationally selected to
precisely treat patients with similar molecular “ﬁngerprints”. By
speciﬁcally tailoring treatments to molecular dysregulations driv-
ing the emergence of cancer as well as resistance mechanisms,
more tolerated, effective, durable regimens can be crafted to treat
a patient's disease biology.Conﬂict of interest
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